Thrombolytic Treatment for Myocardial Infarction: Highlighting Healthcare Affordability and Drug Market Segmentation in India

posted Nov 25, 2016, 1:48 AM by Vaishnavi Sundar   [ updated Nov 30, 2016, 2:01 AM ]

 

This study looks at the available life-saving treatments for heart attacks and ischaemic heart diseases administered in India, focusing on streptokinase and finding that it is the life-saving clot-buster for the majority of patients. This brings to light that the surgical intervention of angioplasty is more of an income-biased treatment. Public-funded research and development of indigenous streptokinase has directly enabled access to treatment, especially for economically challenged patients. Read more at: http://www.epw.in/journal/2016/38/commentary/thrombolytic-treatment-myocardial-infarction.html#sthash.FqhUOZn0.gbpl
Comments